EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterization of Anti-Canine PD-1 Antibodies

Colin J Hartman, Petra Sergent, Anna Barbara Emilia Zimmermann, Olga R Chávez-Alexander-Anderson, Luis A Perez Alonso, Louise Lines, Juan Carlos Pinto-Cárdenas iD, Daniel Luna Dávalos, Anna M Schmoker iD, Scott M Palisoul, Johannes Vom Berg iD, Xiaoxuan Ge iD und 5 weitere

Cells · 23.05.2026 · 15 (11) · 966

DOI: 10.3390/cells15110966 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 23.05.2026. Verfasst von Colin J Hartman und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, 621 Rubin Building-HB7936, 1 Medical Center Drive, Lebanon, NH 037…. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, GLF funding, NCI Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer is a leading cause of death in dogs, and incidence rates in dogs exceed those in humans. Current therapeutic options for canine cancer patients remain limited, with most treatments focused on palliative care. Immune checkpoint inhibitors such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies that have transformed cancer therapy and expanded the therapeutic options in humans could offer the same clinical benefit in canine cancer patients. This study details the engineering and functional characterization of mouse and chimeric mouse–canine anti-canine PD-1 (cPD-1) monoclonal antibodies. We demonstrate that anti-cPD-1 antibodies block the interaction between cPD-1 and its ligand cPD-L1, thereby inhibiting this immune signaling pathway. In a proof-of-concept study in seven companion canine cancer patients, intratumoral therapy with the lead anti-cPD-1 antibody (HugPetmab) was safe, well-tolerated, had no observed adverse events, and showed evidence of tumor control in a subset of injected tumors. These findings support the potential of HugPetmab antibody as an immunotherapeutic option for treating canine cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Programmed Cell Death 1 ReceptorAntibodies, MonoclonalNeoplasmsAnimalsDogsHumansMiceFemaleCell Line, Tumor

Stichwörter der Autor:innen

antibodycancercaninemammary tumorsmast cell tumorspreclinical trialtherapeutic antibodies

Substanzen

Programmed Cell Death 1 ReceptorAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, 621 Rubin Building-HB7936, 1 Medical Center Drive, Lebanon, NH 03756, USA.
  • Clinic for Radiation Oncology and Medical Oncology, University Animal Hospital, Vetsuisse Faculty, University of Zurich, 8057 Zurich, Switzerland.
  • Institute of Laboratory Animal Science, University of Zurich, 8952 Schlieren, Switzerland.
  • Villareal Garza, Hospital Veterinario, Monterrey 64390, Mexico.
  • DIAGSA, Diagnóstico de Salud Animal, Naucalpan 53910, Mexico.
  • VETCONNECT Diagnóstico por Imagen, Monterrey 64780, Mexico.

ORCID-Profile: Juan Carlos Pinto-Cárdenas, Anna M Schmoker, Johannes Vom Berg, Xiaoxuan Ge, Jay L Rothstein, Margaret E Ackerman, Steven Fiering, Hugo Arias-Pulido

Förderung

  • NIH HHS
  • GLF funding
  • NCI Cancer Center

Zitieren

APA

Hartman, C. J., Sergent, P., Zimmermann, A. B. E., Chávez-Alexander-Anderson, O. R., Perez Alonso, L. A., Lines, L., Pinto-Cárdenas, J. C., Luna Dávalos, D., Schmoker, A. M., Palisoul, S. M., Vom Berg, J., Ge, X., Rothstein, J. L., Ackerman, M. E., Fiering, S., Noelle, R. J., & Arias-Pulido, H. (2026). Characterization of Anti-Canine PD-1 Antibodies. Cells, 15(11), 966. https://doi.org/10.3390/cells15110966

Vancouver

Hartman CJ, Sergent P, Zimmermann ABE, Chávez-Alexander-Anderson OR, Perez Alonso LA, Lines L, et al. Characterization of Anti-Canine PD-1 Antibodies. Cells. 2026;15(11):966. doi:10.3390/cells15110966

BibTeX
@article{Hartman2026,
  author = {Hartman, Colin J and Sergent, Petra and Zimmermann, Anna Barbara Emilia and Chávez-Alexander-Anderson, Olga R and Perez Alonso, Luis A and Lines, Louise and Pinto-Cárdenas, Juan Carlos and Luna Dávalos, Daniel and Schmoker, Anna M and Palisoul, Scott M and Vom Berg, Johannes and Ge, Xiaoxuan and Rothstein, Jay L and Ackerman, Margaret E and Fiering, Steven and Noelle, Randolph J and Arias-Pulido, Hugo},
  title = {Characterization of Anti-Canine PD-1 Antibodies},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {11},
  pages = {966},
  doi = {10.3390/cells15110966}
}
Kostenlos starten →